 |
24 Diseases |  |
14 Trials |
|
14 Trials |  |
566 News |  |
| «12345678» |
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (clinicaltrials.gov) - May 31, 2018
P4, N=64, Recruiting, Sponsor: Fundacion SEIMC-GESIDA
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Sep 2018
- | Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: PEP2: Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (clinicaltrials.gov) - Apr 19, 2018
P1, N=58, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (clinicaltrials.gov) - Apr 9, 2018
P3, N=100, Recruiting, Sponsor: Ospedale San Raffaele
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Apr 3, 2018
P3b, N=166, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date: Open-label Safety Study of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Mar 21, 2018
P3, N=252, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial completion date: Jun 2018 --> Sep 2018
- | Prezista (darunavir) / J&J, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P1 trial: PEP2: Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (clinicaltrials.gov) - Mar 20, 2018
P1, N=58, Not yet recruiting, Sponsor: Emory University
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: WAVES: Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (clinicaltrials.gov) - Mar 15, 2018
P3b, N=583, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Jun 2018 --> Sep 2018 Trial completion date: Jun 2018 --> Sep 2018
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Mar 5, 2018
P3b, N=166, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Jun 2018 --> Sep 2018 Trial primary completion date: Feb 2018 --> Feb 2018
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Mar 3, 2018
P2/3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2018 --> Feb 2018 Trial primary completion date: Jun 2018 --> Jul 2018
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Feb 22, 2018
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2018 --> Jul 2018 Trial primary completion date: Jun 2017 --> Dec 2018 | Trial completion date: Jun 2019 --> Sep 2019
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Compliance: Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis (clinicaltrials.gov) - Feb 15, 2018
P3, N=100, Enrolling by invitation, Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Trial primary completion date: Jun 2017 --> Dec 2018 | Trial completion date: Jun 2019 --> Sep 2019 Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Oct 2017 --> Mar 2018 | Trial completion date: Oct 2017 --> Jul 2018 | Initiation date: Jan 2017 --> Mar 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date: Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities (clinicaltrials.gov) - Feb 9, 2018
P1, N=90, Recruiting, Sponsor: Emory University
Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Oct 2017 --> Mar 2018 | Trial completion date: Oct 2017 --> Jul 2018 | Initiation date: Jan 2017 --> Mar 2017 Trial primary completion date: Dec 2017 --> Sep 2018 | Trial completion date: Dec 2017 --> Sep 2018
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New trial: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=200, Not yet recruiting, Sponsor: National Taiwan University Hospital
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion, Trial completion date: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Feb 7, 2018
P3b, N=275, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2017 --> Sep 2018 | Trial completion date: Dec 2017 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New trial: Same-Day Treatment With Genvoya vs. EFV/TDF/3TC (clinicaltrials.gov) - Jan 23, 2018
P=N/A, N=256, Not yet recruiting, Sponsor: Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Efficacy and Safety of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Dec 19, 2017
P3b, N=79, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Active, not recruiting --> Completed
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents (clinicaltrials.gov) - Nov 7, 2017
P2/3, N=60, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents (clinicaltrials.gov) - Oct 23, 2017
P2/3, N=60, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Nov 2016
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Trial completion: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Oct 5, 2017
P3b, N=150, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2017 --> Nov 2016 Active, not recruiting --> Completed
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Sep 20, 2017
P2, N=279, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - Sep 13, 2017
P3, N=55, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Sep 1, 2017
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Trial completion: TAF-IR: Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication (clinicaltrials.gov) - Aug 21, 2017
P1, N=30, Completed, Sponsor: Technische Universit
Active, not recruiting --> Recruiting Recruiting --> Completed
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Aug 17, 2017
P2/3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Jul 16, 2017
P3b, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New trial: Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=72, Recruiting, Sponsor: University of California, Los Angeles
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - May 24, 2017
P=N/A, N=14, Completed, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial initiation date: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (clinicaltrials.gov) - May 5, 2017
P4, N=64, Not yet recruiting, Sponsor: Fundacion SEIMC-GESIDA
Active, not recruiting --> Completed Initiation date: Apr 2017 --> Jul 2017
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - May 2, 2017
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Initiation date: Apr 2017 --> Jul 2017 Trial primary completion date: Oct 2017 --> Jun 2018
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Trial primary completion date: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Apr 26, 2017
P3, N=25, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Trial primary completion date: Oct 2017 --> Jun 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Enrollment open: TAF-IR: Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication (clinicaltrials.gov) - Apr 25, 2017
P1, N=30, Recruiting, Sponsor: Technische Universit
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2017 Not yet recruiting --> Recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Apr 13, 2017
P3b, N=166, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities (clinicaltrials.gov) - Apr 11, 2017
P1, N=90, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
New P1 trial: TAF-IR: Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication (clinicaltrials.gov) - Mar 27, 2017
P1, N=30, Not yet recruiting, Sponsor: Technische Universit
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (clinicaltrials.gov) - Mar 8, 2017
P3b, N=275, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P4 trial: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (clinicaltrials.gov) - Feb 28, 2017
P4, N=64, Not yet recruiting, Sponsor: Fundacion SEIMC-GESIDA
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Feb 23, 2017
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Jun 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial initiation date: Early ART to Limit Infection and Establishment of Reservoir (clinicaltrials.gov) - Feb 17, 2017
P2, N=150, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Jan 2017
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ? 60 Years (clinicaltrials.gov) - Feb 16, 2017
P3b, N=150, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Jan 2017 Trial primary completion date: Apr 2017 --> Feb 2018
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Biomarker, Journal: Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. (Pubmed Central) - Feb 16, 2017
Trial primary completion date: Apr 2017 --> Feb 2018 We observed equivalent declines in biomarkers of monocyte activation and systemic inflammation in treatment-naïve adults treated with TAF or TDF for 48weeks, suggesting that TAF and TDF have equivalent impact on immune activation and inflammation.
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (clinicaltrials.gov) - Feb 10, 2017
P3, N=471, Active, not recruiting, Sponsor: Gilead Sciences
We observed equivalent declines in biomarkers of monocyte activation and systemic inflammation in treatment-naïve adults treated with TAF or TDF for 48weeks, suggesting that TAF and TDF have equivalent impact on immune activation and inflammation. Recruiting --> Active, not recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed, Enrollment change: Co-STARs: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (clinicaltrials.gov) - Jan 30, 2017
P3b, N=150, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=240 --> 150
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial, Compliance: Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis (clinicaltrials.gov) - Dec 20, 2016
P3, N=100, Not yet recruiting, Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (clinicaltrials.gov) - Dec 16, 2016
P3b, N=100, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=240 --> 150 Trial primary completion date: Oct 2017 --> Feb 2017
- |||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Enrollment change, Trial primary completion date: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (clinicaltrials.gov) - Dec 7, 2016
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2017 --> Feb 2017 Active, not recruiting --> Recruiting | N=73 --> 100 | Trial primary completion date: Apr 2016 --> Oct 2017
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
New P1 trial: Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities (clinicaltrials.gov) - Dec 6, 2016
P1, N=90, Not yet recruiting, Sponsor: Emory University
- Trial primary completion date: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=2016, Recruiting, Sponsor: University of Zurich
Active, not recruiting --> Recruiting | N=73 --> 100 | Trial primary completion date: Apr 2016 --> Oct 2017 Trial primary completion date: Dec 2015 --> Jan 2025
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=14, Active, not recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Dec 2015 --> Jan 2025 Recruiting --> Active, not recruiting
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open, Trial primary completion date: CTN289: HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (clinicaltrials.gov) - Oct 20, 2016
P3, N=25, Recruiting, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Jul 2017
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (clinicaltrials.gov) - Oct 19, 2016
P3b, N=50, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2017 --> Jul 2017 Recruiting --> Active, not recruiting